Resources

When pricing for CGM systems comes down to less than using a blood glucose monitor with strips, will you recommend these to your patients who do not take insulin?

- Yes
- No
- For my patients who are motivated
- For my patients who are not motivated

Follow the link to see how you and your colleagues compare.

Which of the following is accurate regarding the treatment and management of hypertriglyceridemia?

A. Pharmacologic therapy is typically initiated before lifestyle modifications in the treatment of primary and secondary dyslipidemia.
B. Patients can be treated before hypertriglyceridemia is confirmed.
C. Niacin raises LDL cholesterol levels.
D. High-potency statin monotherapy is recommended for severe or very severe hypertriglyceridemia.

Follow the link for the answer.

It’s not unusual for people who have excess weight or obesity to have many barriers to overcome in managing their weight. In my experience, the holiday season can be a big barrier. For much of the world, holidays are associated with food; not just food but an overabundance of food. And for many, the weather is cold at this time of the year, which doesn’t help with being active.

Raghu Mirmira, MD, PhD, is the director of the Center for Diabetes and Metabolic Diseases (CDMD) at Indiana University School of Medicine. Under his leadership, the NIH-funded CDMD at IU School of Medicine strives to transform health through basic and translational research while preparing healers with enhanced opportunities in diabetes research and scientific discovery. The focus of Dr. Mirmira’s research is the pathogenesis of diabetes mellitus and the biology of the islet. His most recent areas of interest include islet stress pathways in Type 1 diabetes and how these pathways contribute to the production of neoantigens and the activation of autoimmune responses.

In this week's Homerun Slides, understanding the DIAMOND study of people with type 1 and type 2 diabetes.

Maturity-onset diabetes of the young (MODY) refers to group of monogenic subtypes of diabetes characterized by young onset (usually before 25 years) of non-insulin-dependent diabetes, beta-cell dysfunction that is inherited as an autosomal dominant trait. Mutations in at least 10 genes have been found to cause MODY; the common subtypes are due to mutations in GCK, Hepatocyte nuclear factor 1-alpha (HNF1A), HNF4A, and HNF1B. The definition of the underlying genes has resulted in the recognition of distinct clinical and physiologic subgroups of MODY with varying clinical course, prognosis, and treatment requirements. Classifications of diabetes by the ADA and the WHO recognize these discrete subtypes.

In this Exclusive Interview transcript, Raghu Mirmira talks with Diabetes in Control publisher Steve Freed during the ADA 2018 convention in Orlando about his work as type 1 diabetes researcher, beta cell replacement, and ER Stress.

In this Exclusive Interview, Raghu Mirmira talks with Diabetes in Control publisher Steve Freed during the ADA 2018 convention in Orlando about his research in type 1 diabetes, beta cell replacement, and ER Stress.

In part 1 of this Exclusive Interview, Raghu Mirmira talks with Diabetes in Control Publisher Steve Freed about the need to look at other aspects of diabetes beyond autoimmunity.

In part 2 of this Exclusive Interview, Raghu Mirmira talks with Diabetes in Control Publisher Steve Freed about the complex components that complicate the success of beta cell replacement.